GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foamix Pharmaceuticals Ltd (NAS:FOMX) » Definitions » Gross Property, Plant and Equipment

Foamix Pharmaceuticals (Foamix Pharmaceuticals) Gross Property, Plant and Equipment : $5.81 Mil (As of Dec. 2019)


View and export this data going back to 2014. Start your Free Trial

What is Foamix Pharmaceuticals Gross Property, Plant and Equipment?

Foamix Pharmaceuticals's quarterly gross PPE increased from Jun. 2019 ($4.36 Mil) to Sep. 2019 ($4.76 Mil) and increased from Sep. 2019 ($4.76 Mil) to Dec. 2019 ($5.81 Mil).

Foamix Pharmaceuticals's annual gross PPE increased from Dec. 2017 ($2.85 Mil) to Dec. 2018 ($3.22 Mil) and increased from Dec. 2018 ($3.22 Mil) to Dec. 2019 ($5.81 Mil).


Foamix Pharmaceuticals Gross Property, Plant and Equipment Historical Data

The historical data trend for Foamix Pharmaceuticals's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foamix Pharmaceuticals Gross Property, Plant and Equipment Chart

Foamix Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Gross Property, Plant and Equipment
Get a 7-Day Free Trial 1.32 1.61 2.85 3.22 5.81

Foamix Pharmaceuticals Quarterly Data
Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.22 4.23 4.36 4.76 5.81

Foamix Pharmaceuticals Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Foamix Pharmaceuticals  (NAS:FOMX) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Foamix Pharmaceuticals Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Foamix Pharmaceuticals's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Foamix Pharmaceuticals (Foamix Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2 Holzman Street, Weizmann Science Park, Rehovot, ISR, 7670402
Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company. It is focused on the development and commercialization of foam based formulations and topical drugs for dermatological therapies mainly acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103, FDX104. The firm also has development and license agreements relating to its technology with various pharmaceutical companies. It has The development and commercialization of foam based formulations segment.
Executives
Ilan Hadar officer: CFO & Country Manager C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Stanley Hirsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Aharon Schwartz director C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET, SCIENCE PARK, #455, CARMIEL L3 20100
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Anna Kazanchyan director 933 MAMARONECK AVENUE, SUITE 103, MAMARONECK NY 10543
Anthony D Bruno director C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Stanley Stern director C/O THCG, INC, 650 MADISON AVENUE, 21ST FL, NEW YORK NY 10022
Rex Bright director 5641 LAKE VISTA DRIVE, BONSALL CA 92003
Iain Stuart officer: Chief Scientific Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
David Domzalski director, officer: CEO C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Mutya Harsch officer: CLO and General Counsel C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Matthew T. Wiley officer: Chief Commercial Officer C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003

Foamix Pharmaceuticals (Foamix Pharmaceuticals) Headlines

From GuruFocus